Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CRSP
CRSP logo

CRSP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CRSP News

CRISPR Therapeutics Faces Commercialization Challenges

1d agoFool

CRISPR Therapeutics Faces Market Challenges Amid Progress

1d agoNASDAQ.COM

Biotech Sector Thrives with Strong Growth Potential

2d agoFool

Investment Opportunities in Biotech Stocks

2d agoNASDAQ.COM

Investment Portfolio Strategy Analysis

2d agoFool

Investment Strategy Analysis for Blue Chip Stocks

2d agoNASDAQ.COM

CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline

Jun 08 2026Fool

CRISPR Therapeutics Shows Promising Future Potential

Jun 03 2026Fool

CRSP Events

06/11 14:30
Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B
Jeff Bezos' new AI venture Prometheus has raised $12B in fresh funding, pushing its valuation to about $41B. Meanwhile, OpenAI confidentially filed for an IPO with the SEC, setting up a potential race with Anthropic as both companies seek massive new capital.This week's private company news:OpenAI announced that it will acquire Ona, "bringing its secure cloud execution and orchestration technology into our rapidly expanding Codex ecosystem." OpenAI said: "As Codex becomes more capable, its most valuable work is unfolding over hours or days, rather than minutes. We believe people should be able to delegate more ambitious work without remaining tied to the machine where it began. The work should continue beyond the initial session, with Codex making it possible to stay connected and check progress, provide direction, make decisions, and review results from anywhere. Ona will help us do that. Its technology provides secure, persistent environments where agents can access the tools, systems, and context they need to make progress over time."Sam Altman, CEO of Microsoft-backed OpenAI, and the Trump administration are in ongoing discussions over a possible government stake in the ChatGPT maker, CNBC's Ashley Capoot and Kate Rooney. The talks have been in progress for over a year, as Altman first shared the idea with the White House last year, the authors say, citing a source familiar with the matter. Such discussions continued this week as the CEO met with a number of lawmakers and officials in Washington, D.C. to go over regulation and the latest developments in AI, the authors note. As part of a potential pact, OpenAI could donate equity to the U.S. government to seed something in the vein of a "Public Wealth Fund" that the ChatGPT maker outlined in its April policy proposal, the authors say.Some of the biggest capital raises by private companies this week include:Prometheus- Jeff Bezos' newest AI venture has secured a massive $12B funding round. Prometheus launched in November with $6.2B in initial backing and is now valued at roughly $41B. The latest funding round includes investments from JPMorgan Chase, Goldman Sachsand BlackRock. Publicly-traded companies operating in the same space include Microsoft, IBM, and Palantir.NEURA Robotics– The cognitive robotics company and creator of the Neuraverse announced a Series C financing with a total round size of up to $1.4B to accelerate its mission of building the world's leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure, including Tether, Qualcomm, Amazon, Nvidia, imec.xpand, Bosch, Schaeffler, European Investment Bank, Lingotto Horizon, InterAlpen Partners and others. Publicly-traded companies operating in the same space include Tesla, Symbotic, and iRobot.Cyera– The cybersecurity startup raised $600M at a $12B valuation in a round led by Evolution Equity Partners, with participation from Cyberstarts and Temasek, in addition to all existing investors including Accel, AT&T Ventures, Blackstone, Coatue, Spark Capital, among others. Publicly-traded companies operating in the same space include Palo Alto Networks, CrowdStrike, and Fortinet.Flourish– The company said it raised $500M at a $2.5B valuation, with Amazonfounder Jeff Bezos contributing nearly $100M. Publicly-traded companies operating in the same space include AeroVironment.Helion– The Washington-based fusion energy company announced a $465M Series G investment round that was led by Thrive Capital. Publicly-traded companies operating in the same space include Chevron, Nucor, and AMSC.Unicorns to watch this week:Insilico Medicine– The AI-driven drug discovery startup recently raised to unicorn status with its latest funding round. The company uses generative AI to design small molecule drugs and accelerate preclinical development. Publicly-traded companies operating in the same space include Exscientiaand Recursion Pharmaceuticals.Innovaccer– The healthcare AI unicorn, valued at about $3.45B, is focusing on acquisitions and secondary rounds as it expands its healthcare data and analytics platform. Publicly-traded companies operating in the same space include Phreesia, IQVIA, and CareCloud.Dataiku– The AI/machine-learning platform helps enterprises build, deploy and manage models. Publicly-traded companies operating in the same space include Altair, Google, and IBM.Mammoth Biosciences– The company focuses on CRISPR-based diagnostics and therapeutics, using novel CRISPR systems. Publicly-traded companies operating in the same space include CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics.Apex Space– The space company, which builds satellite platforms for commercial and government customers, recently reached unicorn status as demand for space based networks accelerates. Publicly-traded companies operating in the same space include Redwire, AST SpaceMobile, and Iridium Communications.Other IPOs to watch:OpenAI– The company has confidentially filed for an IPO with the SEC, which allows the company to submit its financials to regulators for review before they're made available to the public, CNBC.com's Ashley Capoot. Anthropic and OpenAI could be in a race to go public due to the massive amount of capital they're trying to raise, the report states.Bending Spoons– The technology company whose main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "BSP."Kardigan– The company has filed an initial public offering of shares of its common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "KARD." JP Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as the underwriters for the offering.SpaceX– The company has officially submitted its Form S-1 with the SEC to list its Class A common stock on the Nasdaq under the ticker symbol SPCX. Expected to be the largest IPO in history, the company targets raising up to $80B at a valuation exceeding $2T.Inspire Brands– The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Private Markets" is The Fly's recurring series of stories on the latest moves in the private sector, largest unicorn companies and initial public offerings to watch. Fly subscribers, add $PRIVATE to your portfolio for alerts on breaking news in the startup and venture capital space.
06/02 09:50
FDA Issues Draft Guidance for Gene Therapies
The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls data, nonclinical study results and clinical information, to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells. "Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible." This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).

CRSP Monitor News

CRISPR Therapeutics Faces Stock Decline Amid Market Weakness

Jun 05 2026

CRISPR Therapeutics Gains FDA Approval for Casgevy, Boosting Stock

Jun 04 2026

CRISPR Therapeutics Gains on Casgevy Approval and Strong Pipeline

May 28 2026

CRISPR Therapeutics Secures Approval for First CRISPR-Based Medicine

Apr 27 2026

CRISPR Therapeutics Secures Approval for First CRISPR-Based Medicine

Apr 24 2026

CRISPR Therapeutics Strengthens Cash Position Amid Pipeline Expansion

Apr 13 2026

CRISPR Therapeutics target price reduced by Leerink Partners

Mar 31 2026

CRISPR Therapeutics Prices $550 Million Convertible Notes Offering

Mar 11 2026

CRSP Earnings Analysis

No Data

No Data

People Also Watch